AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03405493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wake and Light Therapy
Description: Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
Study NCT03405493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Light Therapy
Description: Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
Study NCT00700531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLC removal HD (Gambro HCO 1100)
Description: FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
Study NCT00700531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dialysis on a high flux ployflux dialyser
Description: Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
Study NCT04392206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose Derived Mesenchymal Stem Cells
Description: The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution
Study NCT01303809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Recovery After Surgey for Sleeve Gastrectomy
Description: Intraoperative:~1. Pre-op carbohydrate loading~2. No pre-op GIK while NBM~3. Pre-medication~4. Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg~5. Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics~6. Fluid restriction~7. Standardised method of anaesthesia~8. Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites~9. 10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure~Postoperative:~1. Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively~2. Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1~3. Post operative oxygenation~4. Incentive spirometry~5. Drains (e.g. IDC) removed in recovery~6. Full mobilisation 4-8 hours post op)~7. Early Follow up
Study NCT01991405 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Computerized Working Memory Training.
Description: Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical.
Study NCT03932682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIVc
Description: QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.
Study NCT03932682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Meningococcal Group C Polysaccharide Conjugate Vaccine (MenC vaccine, Neisvac-C)
Study NCT03336827 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive-Behavioral Group Therapy and Hypnosis
Description: The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
Study NCT02062463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX
Description: SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)
Study NCT02062463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYMBICORT TURBOHALER budesonide and formoterol fumarate
Description: SYMBICORT® TURBOHALER® (200/6 and 400/12 μg)
Study NCT04296227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vital Detect blood pressure monitor
Description: The end goal is to provide Non-invasive Blood Pressure (NIBP) accuracy data to support validation of the Vital Detect blood pressure monitor.
Study NCT01641198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Configuration 1
Description: B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
Study NCT01641198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Configuration 2
Description: B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
Study NCT01641198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Configuration 3
Description: B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
Study NCT01694446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose or fructose
Study NCT02706717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visbiome Extra Strength
Description: From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
Study NCT02706717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
Study NCT03634280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
Study NCT00377507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: catechin extracts
Description: catechin extracts solution
Study NCT01388166 — intervention group
Intervention type: PROCEDURE
Intervention: Education
Description: Education
Study NCT00454519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cytoreductive surgery
Description: the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
Study NCT00454519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin
Description: Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
Study NCT03114696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AO-101
Description: 1 dose (sachet) to be consumed 30 - 60 mins before bedtime
Study NCT03114696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
Study NCT03347760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTATOC-68Ga PET initial
Description: DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
Study NCT03347760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTATOC-68Ga PET at 6 months
Description: DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
Study NCT03347760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood tests will be carried out during the control visit to ensure that biological parameters are normalized
Study NCT03631082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slump stretching
Description: Slump stretching will be provided to this group along with standardized exercises.
Study NCT03631082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar mobilization
Description: Lumbar mobilizations will be provided to this group along with standardized exercises.
Study NCT03035552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacifier activated music player
Description: Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
Study NCT03053336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-technology to increase physical activity
Description: Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
Study NCT01426035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G
Description: APLIED 4 TIMES/DAY AT LESION
Study NCT01426035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G
Description: APLIED 4 TIMES/DAY AT LESION
Study NCT00775684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
Study NCT00775684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin (Januvia®)100 mg by mouth every morning
Study NCT00775684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose \< 110mg/dl
Study NCT05224284 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BPA levels
Description: BPA (Bisfenol A) in blood and ejaculate samples
Study NCT01027741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Referral
Description: Participants receive phone referral to cancer control and prevention services.
Study NCT01027741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Cancer Communication
Description: Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
Study NCT01027741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Control Navigator
Description: A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
Study NCT03458637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LITE Program and Usual Care
Description: Family based lifestyle Intervention
Study NCT03458637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care consisting of 3 visits to weight management clinic
Study NCT03458637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care consisting of 3 visits to weight management clinic
Study NCT02809170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Arginine is an amino acids
Study NCT02809170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrulline
Description: Citrulline is an amino acid
Study NCT00391079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg.
Study NCT00391079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
Study NCT01077882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education on skin disease conditions
Description: information about several skin diseases skin function recommendation on care of skin
Study NCT01077882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-reduction techniques
Description: Physical Training yoga mindfulness-based stress reduction
Study NCT01077882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle factors and psycho-education
Description: by dietician and psychiatrist
Study NCT01077882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no educational program
Description: standard care without educational program
Study NCT01690221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN 307
Description: VEN307 applied three times a day, in and around the anus, for 28 days.
Study NCT01690221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream applied three times a day, in and around the anus, for 28 days.
Study NCT00767065 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Computed Tomography
Description: Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate \<70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
Study NCT00767065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
Study NCT00112346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + platinum + gemcitabine
Description: Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
Study NCT00112346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum + Gemcitabine
Description: Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
Study NCT05033366 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proov Test
Description: Rapid response urine PdG, FSH, E1G and LH test strips, Proov
Study NCT03533374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram (EEG) and visual evaluation
Description: Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
Study NCT04593017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Probiotic
Description: Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
Study NCT04593017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Probiotic
Description: Placebo
Study NCT04658836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Intratympanic application of triamcinolone acetonide
Study NCT01168765 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tu Salud Si Cuenta Behavioral Intervention
Description: A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
Study NCT01168765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tu Salud Si Cuenta Behavioral Intervention
Description: A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
Study NCT02031952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatectomy combined with lymphadenectomy
Study NCT02031952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatectomy alone
Study NCT03589521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABCT_Military
Description: 15 Weekly Couple Therapy Sessions
Study NCT02199054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wheat-safflower oil pretzels
Description: Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
Study NCT02199054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: soy-safflower oil pretzels
Description: Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
Study NCT02199054 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control wheat pretzels
Description: Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
Study NCT01408095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2608204
Description: Administered orally
Study NCT01408095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Administered orally
Study NCT04175743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-044 HCl
Description: CT-044 HCl is a reactive species decomposition accelerant
Study NCT03651466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gx-G6
Description: Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
Study NCT03651466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.